Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRB-001 in Early Idiopathic Parkinson's Disease
NCT07840027Phase 1Recruiting
- Sponsor
- Tridem Bioscience
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TRB-001 in Parkinson's disease (PD) (3 arms), sponsored by Tridem Bioscience. Primary endpoints: Treatment-Emergent Adverse Events at 6 months and Immunogenicity of TRB-001 at 6 months. Started Sep 2026; status: recruiting.
02
Drugs
TRB-001
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07840027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07840027.